Theradaptive Expands Leadership Team with Appointment of Daniel Wolf as CFO

Theradaptive Welcomes Daniel Wolf as Chief Financial Officer

Theradaptive, a leading clinical-stage biotechnology firm renowned for its innovative protein therapeutics aimed at tissue regeneration, has officially appointed Daniel Wolf as its Chief Financial Officer (CFO). This strategic addition to the executive team is seen as a significant step in the company's ongoing transformation.

Wolf comes to Theradaptive with an impressive résumé, boasting over 20 years of executive experience within the medical device and healthcare industries. His prior roles include high-ranking positions at renowned companies such as Medtronic and Baxter International. At Baxter, he was the Senior Vice President and Chief Strategy and Mergers & Acquisitions Officer, overseeing pivotal growth strategies and mergers in the healthcare domain.

Before his tenure at Baxter, Daniel spent more than 12 years at Medtronic, where he held several key leadership roles, particularly within the Spine and Biologics division. His extensive experience includes serving as President of Medicrea as well as Vice President and General Manager of Intelligent Data Solutions. This wealth of experience has equipped him with a profound understanding of strategic transactions, corporate development, and healthcare economics.

Dr. Luis M. Alvarez, Founder and CEO of Theradaptive, expressed enthusiasm for Wolf's appointment, stating, "We are delighted to welcome Dan to the Theradaptive team. His proven track record in financial leadership and strategic growth in our field will be crucial as we accelerate towards the commercialization of our targeted therapeutic delivery platform. Moreover, Dan is uniquely prepared to navigate the rising interest from strategic partners and large investors as we head into our Series B funding round this coming summer."

In conjunction with Wolf’s hiring, Theradaptive has begun a broader executive transformation, which includes the recent appointment of Dr. Frank Vizesi as Chief Scientific Officer (CSO) and the addition of Jeffrey Dunn to the Board of Directors. This collective move illustrates the company’s commitment to bolstering its leadership team with seasoned professionals in preparation for potentially high-value periods of growth.

In his statement, Wolf highlighted his admiration for Theradaptive's innovative approach, saying, "Theradaptive's innovative method to targeted therapeutic delivery represents a game-changer in the industry. Its determination to transform patient care is genuinely inspiring. I look forward to working alongside the team to drive the next phase of our growth and deliver substantial value to our patients, partners, and investors."

Jeffrey Dunn, a member of the Board of Directors, praised Wolf, describing him as a world-class leader in the musculoskeletal space, stating, "His deep experience across strategy, finance, and mergers & acquisitions will be vital as the company grows and engages with key industry stakeholders."

Founded in 2017 and based in Frederick, Maryland, Theradaptive is dedicated to pioneering advanced protein engineering technologies for precise therapeutic delivery across a multitude of medical applications, such as spine, orthopedics, and soft tissue repair. Wolf's ascension to the CFO role underscores the company's commitment to enhancing its executive team and positioning itself for exceptional value creation as it completes enrollment for its Phase II clinical studies.

In summary, the appointment of Daniel Wolf as CFO signifies not only a pivotal moment for Theradaptive but also reinforces its commitment to innovate within the healthcare sector by addressing unmet medical needs through groundbreaking therapies. For further information on Theradaptive and its ongoing clinical development initiatives, visit www.theradaptive.com or follow the company on LinkedIn.